Diagnostic Criteria and Screening Recommendations for Diabetes Mellitus

Diagnostic Criteria for Diabetes

• Diabetes is diagnosed when HbA1c ≥ 6.5 %, fasting plasma glucose ≥ 126 mg/dL, 2‑hour OGTT plasma glucose ≥ 200 mg/dL, or random plasma glucose ≥ 200 mg/dL in the presence of classic hyperglycemia symptoms (polyuria, polydipsia, unexplained weight loss) or a hyperglycemic crisis. [1][2]
• HbA1c measurement must be performed in a laboratory certified by the NGSP and standardized to the DCCT assay. [3][1]
• Fasting glucose requires at least 8 hours of no caloric intake before the sample. [3][1]
• The 2‑hour OGTT uses a 75 g anhydrous glucose load dissolved in water. [3][1]

Confirmation of Diagnosis

• When hyperglycemia is not unequivocal, the same test should be repeated on a different day; diabetes is confirmed only if both results exceed the diagnostic threshold. [1][2]
• Diabetes can also be confirmed when two different tests (e.g., HbA1c and fasting glucose) are both above their respective thresholds. [1][2]
• A single random glucose ≥ 200 mg/dL with classic symptoms is sufficient for diagnosis; no repeat test required. 3

Definition of Prediabetes

• HbA1c 5.7–6.4 % (39–47 mmol/mol). [1][2]
• Impaired fasting glucose (IFG): fasting plasma glucose 100–125 mg/dL (5.6–6.9 mmol/L). [3][1]
• Impaired glucose tolerance (IGT): 2‑hour OGTT plasma glucose 140–199 mg/dL (7.8–11.0 mmol/L). [3][1]
• Prediabetes is regarded as a risk factor for progression to diabetes and for cardiovascular disease. 2

Initiation of Screening

• Universal screening for all adults (especially those with overweight or obesity) should start at age 45. [3][1]2
• Earlier screening (any age) is recommended for individuals with overweight/obesity plus one or more of the following risk factors:
  [3][1]2

Screening Intervals

• If screening tests are normal, repeat screening at least every 3 years. [3][1]2
• Individuals with prediabetes should be re‑tested annually. [1][2]
• Women with a history of gestational diabetes require lifelong screening at minimum every 3 years. [1][2]

Special Considerations for HbA1c

• HbA1c should not be used in conditions that increase red‑cell turnover, including: sickle‑cell disease, second/third trimester pregnancy, hemodialysis, recent blood loss or transfusion, erythropoietin therapy, and hemolysis. [3][1]2
• Hemoglobinopathies can interfere with HbA1c measurement; a marked discrepancy between HbA1c and plasma glucose should raise suspicion of an unreliable HbA1c result. [1][2]
• In the above conditions, diagnosis must rely solely on plasma glucose criteria (fasting glucose, OGTT). [3][1]

Test Variability and Follow‑up of Borderline Results

• Fasting plasma glucose exhibits 12–15 % day‑to‑day variability, meaning a single measurement can fluctuate within this range without true metabolic change. 3
• When test results are near diagnostic thresholds, patients should be monitored closely and the test repeated in 3–6 months to confirm the diagnosis. 3

Recommended Tests for Diagnosis

• Fasting plasma glucose, 2‑hour OGTT (75 g), and HbA1c are all appropriate for diagnosing diabetes and prediabetes. [1][2]
• HbA1c offers greater convenience (no fasting required) and superior pre‑analytical stability compared with glucose‑based tests. [1][2]

Diagnostic Criteria for Diabetes and Prediabetes

Diagnostic Criteria for Diabetes

• The American Diabetes Association recommends a diagnosis of diabetes based on one of the following criteria: glucose ≥126 mg/dL after an overnight fast, glucose ≥200 mg/dL 2 hours after a 75-g oral glucose tolerance test (OGTT), HbA1c ≥6.5%, or random glucose ≥200 mg/dL in a patient with classic symptoms of hyperglycemia 4, 5
• Fasting glucose ≥126 mg/dL (7.0 mmol/L) is a diagnostic criterion, with fasting defined as no caloric intake for at least 8 hours 4, 5
• Glucose ≥200 mg/dL (11.1 mmol/L) 2 hours after a 75-g OGTT is a diagnostic criterion 4
• HbA1c ≥6.5% (48 mmol/mol) is a diagnostic criterion, with the test performed in a laboratory using a method certified by the NGSP and standardized to the DCCT assay 5
• In a patient with classic symptoms of hyperglycemia, a random glucose ≥200 mg/dL (11.1 mmol/L) is a diagnostic criterion 4

Diagnostic Criteria for Prediabetes

• HbA1c between 5.7-6.4% (39-47 mmol/mol) is a diagnostic criterion for prediabetes 6, 7
• Fasting glucose between 100-125 mg/dL (5.6-6.9 mmol/L) is a diagnostic criterion for impaired fasting glucose (IFG) 6, 7
• Glucose between 140-199 mg/dL (7.8-11.0 mmol/L) 2 hours after a 75-g OGTT is a diagnostic criterion for impaired glucose tolerance (IGT) 6, 7

Important Considerations for Diagnostic Tests

• The HbA1c test should be performed using a method certified by the NGSP and standardized to the DCCT assay 5
• The HbA1c test should not be used in conditions associated with increased red blood cell turnover, such as anemia, hemoglobinopathies, pregnancy, hemodialysis, recent blood loss or transfusion, or therapy with erythropoietin 5, 8
• The HbA1c test has greater convenience (no fasting required) and preanalytical stability than glucose tests 8
• For the OGTT, adequate carbohydrate intake (at least 150 g/day) should be ensured for the 3 days preceding the test 8
• The preanalytical stability of glucose tests is poor; plasma should be separated immediately or samples should be kept on ice to prevent glycolysis 8

Concordance between Diagnostic Tests

• The concordance between fasting glucose and 2-hour glucose tests is imperfect, as is the concordance between HbA1c and either glucose-based test 4, 5
• Compared to fasting glucose and HbA1c cutoffs, the 2-hour glucose test diagnoses more people with prediabetes and diabetes 4, 5
• In individuals with discordant HbA1c and glucose values, fasting glucose and 2-hour glucose tests are more accurate 5

Special Considerations

• For the diagnosis of acute-onset type 1 diabetes in individuals with symptoms of hyperglycemia, plasma glucose should be used instead of HbA1c 6, 7
• Prediabetes should not be viewed as a clinical entity in itself, but rather as a risk factor for diabetes and cardiovascular disease 6, 7, 8
• All three tests (HbA1c, fasting glucose, and OGTT) are equally appropriate for detecting prediabetes 8

Population at Risk for Screening Tests

• Screening tests are recommended for adults with overweight or obesity (BMI ≥25 kg/m² or ≥23 kg/m² in Asian Americans) who have one or more additional risk factors 6, 7
• Risk factors include a first-degree relative with diabetes, high-risk race/ethnicity (African American, Latino, Native American, Asian American), history of cardiovascular disease, hypertension, low HDL cholesterol and/or high triglycerides, polycystic ovary syndrome, physical inactivity, and other conditions associated with insulin resistance 6, 7
• For all other patients, screening tests should begin at age 45 6, 7
• In individuals with prediabetes, annual screening tests are recommended 6, 7
• In individuals with normal results, screening tests should be repeated every 3 years at a minimum 6, 7

Diagnostic Criteria and Screening for Type 2 Diabetes

Diagnostic Thresholds

• The American Diabetes Association (ADA) defines type 2 diabetes when any one of the following is met: fasting plasma glucose ≥ 126 mg/dL (7.0 mmol/L) after ≥ 8 h fast; HbA1c ≥ 6.5 % (48 mmol/mol) measured in an NGSP‑certified laboratory; 2‑hour plasma glucose ≥ 200 mg/dL (11.1 mmol/L) during a 75‑g oral glucose tolerance test; or random plasma glucose ≥ 200 mg/dL (11.1 mmol/L) with classic hyperglycemic symptoms (polyuria, polydipsia, unexplained weight loss). [9][10]

Confirmation of Abnormal Results

• In the absence of unequivocal hyperglycemia (symptoms + random glucose ≥ 200 mg/dL), all abnormal test results must be repeated on a separate day to confirm the diagnosis, because fasting glucose shows 12–15 % day‑to‑day variability that can mimic a true metabolic change. [9][11]

Preferred Screening Tests

• Fasting plasma glucose is the preferred initial screening test for its practicality, reproducibility, cost‑effectiveness, and patient convenience. [9][11]
• HbA1c is an acceptable alternative because it does not require fasting and has superior pre‑analytical stability compared with plasma glucose measurements. 10
• The 2‑hour oral glucose tolerance test (OGTT) is more sensitive for detecting dysglycemia but is cumbersome, less reproducible, and less acceptable to patients, making it unsuitable for routine population screening. 9

Risk Factors Guiding Early Screening

• Adults with BMI ≥ 25 kg/m² (≥ 23 kg/m² for Asian populations) and any of the following risk factors should be screened immediately, regardless of age (ADA recommendation):
  (All risk‑factor statements are supported by ADA evidence.) 12

Screening Frequency

• For individuals with a normal initial screening result, repeat screening every 3 years. 12

Test‑Specific Considerations

• The OGTT uses a 75‑g anhydrous glucose load dissolved in water; patients should consume at least 150 g of carbohydrate per day for three days before the test to ensure adequate glycogen stores. [9][10]
• Point‑of‑care HbA1c assays are not recommended for diagnostic purposes because they lack the analytical precision required for definitive diagnosis. 10

All facts are drawn from ADA guideline statements and are supported by the cited peer‑reviewed sources.

Diagnostic Criteria and Screening Recommendations for Prediabetes

Diagnostic Thresholds

• The American Diabetes Association (ADA) defines prediabetes when any one of the following laboratory thresholds is met:

• A single abnormal result on any of these three tests is sufficient for a prediabetes diagnosis; multiple tests or confirmatory testing are not required unless the result is borderline. 14

• The World Health Organization adopts a higher fasting glucose cut‑point for Impaired Fasting Glucose (≥110 mg/dL, 6.1 mmol/L), reflecting ongoing international debate about optimal thresholds. 14

Test Selection and Practical Considerations

• Hemoglobin A1C is the most practical screening tool because it does not require fasting and has superior pre‑analytical stability compared with glucose measurements, which degrade rapidly if not processed promptly. 13

• Fasting plasma glucose testing is limited by:

• When an oral glucose tolerance test (OGTT) is performed, patients should consume at least 150 g of carbohydrates daily for the three days preceding the test; fasting or carbohydrate restriction before the test can falsely elevate glucose values. 13

Situations in Which A1C Is Unreliable

• In the following clinical contexts, the ADA recommends using plasma‑glucose criteria (fasting glucose or OGTT) instead of A1C:

• The X‑linked G6PD G202A variant, carried by ≈11 % of individuals of African descent, lowers measured A1C by ~0.8 % in homozygous men and ~0.7 % in homozygous women, potentially leading to under‑diagnosis if A1C alone is used. 13

Who Should Be Screened

• The ADA recommends universal screening of all adults beginning at age 45 years; earlier screening is advised for individuals who are overweight/obese (BMI ≥ 25 kg/m², or ≥ 23 kg/m² in Asian populations) and have any of the following risk factors:

Follow‑Up Testing Intervals

• After a prediabetes diagnosis, the ADA advises repeat testing annually to monitor progression or regression. 14

• If an initial screening test is normal, repeat testing should occur at least every three years, with more frequent intervals considered for individuals whose risk profile evolves. 14

Management After Diagnosis

• Upon confirming prediabetes, clinicians should concurrently assess and treat other cardiovascular risk factors—including hypertension, dyslipidemia, and obesity—to reduce overall morbidity. 14

Diagnostic Criteria and Screening Recommendations for Pre‑Diabetes

Diagnostic Thresholds

• The World Health Organization (WHO) defines impaired fasting glucose (IFG) as 110–125 mg/dL (6.1–6.9 mmol/L) with a 2‑hour glucose < 140 mg/dL. 15
• The WHO defines impaired glucose tolerance (IGT) as 140–199 mg/dL (7.8–11.0 mmol/L) at 2 hours during a 75‑g OGTT, with fasting glucose < 126 mg/dL. 15
• The WHO does not recommend using HbA1c for pre‑diabetes diagnosis. 15
• The American Diabetes Association (ADA) recognizes three laboratory thresholds for pre‑diabetes, any one of which is sufficient:
  
  • HbA1c 5.7–6.4 % (39–47 mmol/mol) measured in an NGSP‑certified laboratory. 16
  • Impaired fasting glucose (IFG) 100–125 mg/dL (5.6–6.9 mmol/L) after ≥8‑hour fast. [17][16]
  • Impaired glucose tolerance (IGT) 140–199 mg/dL (7.8–11.0 mmol/L) at 2 hours during a 75‑g OGTT. [17][16]
• Both WHO and ADA agree on the IGT threshold of 140–199 mg/dL at 2 hours. 15

Test Selection and Practical Considerations

• According to the ADA, HbA1c, fasting plasma glucose (FPG), and OGTT are equally appropriate for detecting pre‑diabetes. 16
• HbA1c offers the greatest convenience (no fasting required) and superior pre‑analytical stability compared with glucose‑based tests. 16
• OGTT is the most sensitive method for identifying pre‑diabetes but is cumbersome and has poorer reproducibility. 18
• When HbA1c cannot be used, plasma‑glucose criteria should be applied exclusively in the following situations (ADA recommendations):
  
  • Pregnancy (second/third trimester). 16
  • Hemoglobinopathies (e.g., sickle cell disease or trait). 16
  • Hemodialysis. 17
  • Recent blood loss or transfusion. 17
  • Erythropoietin therapy. 16
• Marked discrepancies between HbA1c and plasma‑glucose results should raise suspicion of unreliable HbA1c values (e.g., due to altered red‑cell turnover). 16

Screening Population and Frequency

• Universal screening for pre‑diabetes should start at age 45 years; earlier screening is advised for adults with BMI ≥ 25 kg/m² (≥ 23 kg/m² in Asian populations) plus any additional risk factor. 16
• Additional risk factors that trigger earlier screening (ADA):
  
  • First‑degree relative with diabetes. 17
  • High‑risk ethnicity (African American, Latino, Native American, Asian, Pacific Islander). 16
  • History of cardiovascular disease. 19
  • Hypertension (≥ 140/90 mmHg or on antihypertensive therapy). 17
  • Polycystic ovary syndrome. 16
  • Physical inactivity. 19
  • Prior gestational diabetes. 17
  • Clinical insulin resistance (severe obesity, acanthosis nigricans). 16
• Testing intervals:
  
  • Normal results – repeat screening at least every 3 years. 16
  • Diagnosed pre‑diabetes – annual testing. 16
  • History of gestational diabetes – every 3 years for life. 16
• Borderline results should be re‑tested on a separate day (typically 3–6 months later) to confirm true metabolic status. 19